

Review Article

Artificial intelligence in psychiatry: transforming diagnosis, risk prediction and personalized mental healthcare – a narrative review

Rehana Banoo¹, Shilki Sharma², Nathiya K.³, Smriti G. Solomon⁴, Pooja Shree Mazumdar⁵,
T. Aruna^{6,7}, Mayanglambam Sankerdev Singh⁸, Mohammed Umar^{9*},
Simon Samuvel S.¹⁰, P. Emmanuel Raju¹¹

¹Department of Nursing, Government Nursing College, Government Medical College (GMC) Doda, University of Jammu, Doda, Jammu and Kashmir, India

²Department of Mental Health Nursing, Saraswathi College of Nursing, Hapur, Atal Bihari Vajpayee Medical University (ABVMU), Lucknow, Uttar Pradesh, India

³Department of Mental Health Nursing, (Research Scholar) Saveetha College of Nursing, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, Tamil Nadu, India

⁴Department of Mental Health Nursing, Index Nursing College, Malwanchal University, Indore, Madhya Pradesh, India

⁵Department of Mental Health Nursing, AECS Maaruti College of Nursing, Rajiv Gandhi University of Health Sciences (RGUHS), Bengaluru, Karnataka, India

⁶Department of Obstetrics and Gynecological Nursing, College of Nursing Sciences, Dayananda Sagar University; ⁷Chettinad Academy of Research and Education (CARE), Bengaluru, Karnataka/ Chennai, Tamil Nadu, India

⁸Department of Mental Health Nursing, Madhubani Institute of Nursing and Paramedical Sciences, Madhubani, Bihar, India

⁹Department of Nursing, Uttar Pradesh University of Medical Sciences (UPUMS), Saifai, Uttar Pradesh, India

¹⁰Department of Psychiatric Nursing, T. S. Misra College of Nursing, T. S. Mishra University, Anora, Lucknow, Uttar Pradesh, India

¹¹Department of Mental Health Nursing, Holy Faith College of Nursing, Dr. N.T.R. University of Health Sciences, Visakhapatnam, Andhra Pradesh, India

Received: 04 August 2026

Accepted: 24 September 2026

*Correspondence:

Mohammed Umar,

E-mail: umarrathore0786@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Artificial intelligence (AI) is transforming psychiatric practice by introducing innovative approaches to diagnosis, risk prediction, and personalized mental healthcare. Recent advances in machine learning (ML), deep learning (DL), natural language processing (NLP), digital phenotyping, neuroimaging analytics, and wearable technologies have enhanced the ability to analyze complex clinical, behavioral, and biological data, enabling earlier detection of mental disorders and more accurate prediction of treatment outcomes. AI-assisted clinical decision support systems facilitate the identification of individuals at risk of depression, schizophrenia, bipolar disorder, anxiety disorders, suicide, and relapse while supporting precision psychiatry through individualized treatment recommendations. Furthermore, digital health technologies allow continuous monitoring of patients in real-world settings, promoting timely interventions and improving continuity of care. Despite these promising developments, several challenges remain, including algorithmic bias, limited external validation, lack of explainability, data privacy concerns, ethical issues, and regulatory barriers that may affect clinical implementation. This narrative review synthesizes current evidence regarding the applications of AI in psychiatric diagnosis, predictive analytics, and personalized mental healthcare, while critically discussing technological advances, clinical benefits, implementation challenges, ethical considerations, and future research directions. The review highlights that AI should complement rather than replace psychiatrists, supporting evidence-based, patient-centered, and precision mental healthcare. Continued multidisciplinary collaboration, rigorous validation, transparent AI models, and robust governance frameworks are essential to ensure the safe, equitable, and effective integration of AI into routine psychiatric practice.

Keywords: Artificial intelligence, Psychiatry, Machine learning, Deep learning, Precision psychiatry, Mental health, Risk prediction, Personalized mental healthcare, Natural language processing, Digital phenotyping

INTRODUCTION

Psychiatric disorders represent one of the leading causes of disability worldwide, affecting hundreds of millions of individuals and contributing substantially to the global burden of disease. Conditions such as depression, schizophrenia, bipolar disorder, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, and substance use disorders are associated with profound personal suffering, impaired social functioning, reduced productivity, increased healthcare utilization, and elevated mortality. Despite remarkable advances in neuroscience and psychopharmacology, psychiatric diagnosis remains largely dependent on subjective clinical assessments, patient interviews, behavioral observations, and standardized diagnostic criteria such as the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-11).^{1,2}

The absence of reliable biological markers, combined with significant symptom overlap among psychiatric disorders, often complicates diagnostic accuracy and delays appropriate intervention. Variability in clinician expertise, patient self-reporting, cultural influences, and fluctuating symptom presentation further contribute to diagnostic uncertainty. Consequently, mental healthcare systems worldwide continue to face challenges in early detection, individualized treatment selection, relapse prevention, and long-term outcome prediction.³⁻⁵

AI has emerged as one of the most transformative technologies capable of addressing these longstanding limitations in psychiatric practice. AI encompasses computational techniques that enable machines to perform tasks traditionally requiring human intelligence, including pattern recognition, prediction, reasoning, natural language understanding, and adaptive learning. ML, DL, NLP, reinforcement learning, computer vision, and generative AI collectively constitute the technological foundation supporting modern AI applications in healthcare.⁶⁻⁸

Psychiatry presents a particularly suitable domain for AI because mental illnesses generate large volumes of heterogeneous data, including electronic health records, neuroimaging findings, genomic profiles, digital behavioral data, speech characteristics, wearable sensor outputs, social media activity, and patient-reported outcomes. AI algorithms can integrate these multidimensional datasets to identify subtle relationships that may remain undetectable through conventional statistical analyses or routine clinical evaluation. Such capabilities have accelerated research into precision psychiatry, where diagnosis, prognosis, and treatment decisions are increasingly informed by individualized risk profiles rather than generalized diagnostic categories.⁹⁻¹¹

Recent developments demonstrate that ML algorithms can distinguish between psychiatric disorders with promising accuracy using structural and functional neuroimaging

data, electroencephalography, speech patterns, facial expressions, and physiological biomarkers. DL techniques have shown considerable potential in recognizing depressive symptoms through voice modulation, facial affect, and linguistic patterns, while NLP models can analyze clinical notes and patient narratives to identify emerging psychiatric symptoms and suicide risk. Wearable devices and smartphone-based digital phenotyping further enable continuous monitoring of sleep, physical activity, mobility, communication behavior, and social interaction, thereby facilitating early identification of clinical deterioration before overt symptom manifestation.¹²⁻¹⁵

Risk prediction represents another rapidly evolving application of AI in psychiatry. Suicide remains among the leading causes of death globally, yet predicting suicidal behavior through conventional clinical assessment remains challenging because suicidal ideation fluctuates over time and many patients may not disclose their intentions. ML models trained on large-scale healthcare databases have demonstrated improved predictive performance for suicide attempts, psychiatric hospitalization, medication non-adherence, and relapse risk compared with traditional risk assessment approaches. Similarly, predictive analytics have been increasingly applied to identify individuals at high risk of psychosis, dementia, substance dependence, and treatment-resistant depression, allowing clinicians to implement preventive interventions at earlier stages of disease progression.¹⁶⁻¹⁹

The growing emphasis on personalized mental healthcare has further expanded the role of AI in psychiatry. Rather than adopting a "one-size-fits-all" treatment approach, AI-driven predictive models can estimate individual responses to antidepressants, antipsychotics, psychotherapy, neuromodulation, and combined treatment strategies based on demographic, clinical, genetic, and behavioral characteristics. Explainable AI methods have also emerged to improve transparency, enabling clinicians to understand algorithmic recommendations while maintaining accountability in clinical decision-making.²⁰⁻²³

Nevertheless, the widespread implementation of AI in psychiatry raises important ethical, legal, and practical concerns. Algorithmic bias, inadequate external validation, limited interpretability, privacy risks associated with sensitive mental health data, regulatory uncertainty, and potential overreliance on automated systems remain significant barriers to clinical adoption. Ensuring fairness, transparency, patient autonomy, and responsible governance is therefore essential for integrating AI into routine psychiatric practice.²⁴⁻²⁶

Given the rapidly expanding evidence base and the increasing clinical relevance of AI technologies, a comprehensive synthesis of current knowledge is timely. This narrative review critically examines contemporary applications of AI in psychiatric diagnosis, risk prediction,

and personalized mental healthcare while discussing technological advances, clinical implications, implementation challenges, ethical considerations, and future research priorities that may shape the next generation of precision psychiatry.²⁷⁻³⁰

LITERATURE RESEARCH

Review design

This narrative review was undertaken to comprehensively examine current landscape of AI applications in psychiatry, with particular emphasis on diagnostic innovation, predictive analytics, personalized treatment planning, digital mental health technologies, and ethical implications. Unlike systematic reviews that address narrowly defined research questions, a narrative review allows broader integration of multidisciplinary evidence spanning psychiatry, neuroscience, computer science, biomedical informatics, psychology, and digital health. This approach was considered appropriate because AI in psychiatry represents rapidly evolving field characterized

by heterogeneous methodologies, diverse technological platforms, and continuously emerging evidence.

Search strategy

A comprehensive literature search was designed to identify contemporary peer-reviewed studies examining AI in psychiatric practice show in table 1. Searches incorporated controlled vocabulary and free-text keywords combined using Boolean operators. Major search concepts included "artificial intelligence," "machine learning," "deep learning," "natural language processing," "generative artificial intelligence," "large language models," "precision psychiatry," "mental health," "psychiatry," "depression," "schizophrenia," "bipolar disorder," "suicide prediction," "digital phenotyping," "clinical decision support," "predictive analytics," "neuroimaging," "explainable artificial intelligence," and "electronic health records." These terms were combined using "AND" and "OR" operators to maximize retrieval of relevant literature while maintaining specificity.

Table 1: MeSH search strategy and databases used.

Databases	MeSH terms/keywords	Search strategy (Boolean operators)
PubMed/MEDLINE	"Artificial intelligence"[MeSH], "Mental disorders"[MeSH], "Psychiatry"[MeSH], "machine learning", "deep learning", "natural language processing", "precision psychiatry", "risk assessment"	("Artificial intelligence" OR "machine learning" OR "deep learning") AND ("Psychiatry" OR "mental disorders") AND ("Diagnosis" OR "risk assessment" OR "precision psychiatry")
Scopus	Artificial intelligence, psychiatry, mental health, machine learning, digital phenotyping	AI AND psychiatry AND mental health
Web of Science	Artificial intelligence, precision psychiatry, mental disorders	AI AND precision psychiatry
Embase	Artificial intelligence, mental disorders, risk prediction	AI AND mental disorders AND risk prediction
PsycINFO	Psychiatry, depression, suicide prediction, NLP	Psychiatry AND artificial intelligence

Information sources

Evidence was synthesized from multiple internationally recognized scientific databases to ensure comprehensive coverage of medical, psychiatric, computational, and interdisciplinary research. Primary databases included PubMed/MEDLINE, Scopus, Web of Science Core Collection, Embase, PsycINFO, IEEE Xplore Digital Library, ACM Digital Library, ScienceDirect, SpringerLink, Wiley Online Library, and Nature Portfolio journals. Additional evidence was identified through manual screening of reference lists from highly cited reviews, consensus statements, and landmark publications to minimize the likelihood of missing influential studies.

Eligibility criteria

The review primarily included original research articles, prospective cohort studies, retrospective observational studies, randomized clinical trials, multicenter validation studies, narrative reviews, systematic reviews, meta-

analyses, consensus guidelines, and position statements addressing AI applications within psychiatric care. Eligible publications investigated AI-assisted diagnosis, prediction of psychiatric outcomes, personalized treatment selection, digital phenotyping, neuroimaging analytics, wearable technologies, conversational AI, clinical decision support systems, or ethical considerations relevant to psychiatry. English-language publications with substantial scientific relevance were preferentially included to ensure methodological consistency and broad international applicability. Studies lacking sufficient methodological transparency, conference abstracts without peer-reviewed full texts, editorials, opinion articles without empirical evidence, duplicate publications, and studies unrelated to mental health were excluded.

Study selection

Titles and abstracts retrieved through database searches were initially screened according to relevance to the

review objectives. Publications demonstrating potential eligibility underwent full-text assessment to determine their contribution to one or more thematic domains. Particular emphasis was placed on studies reporting clinically applicable AI models, external validation, multicenter datasets, explainability, implementation outcomes, and patient-centered applications. Landmark publications with substantial citation impact were also incorporated to provide historical context regarding the evolution of AI in psychiatry. Preference was given to studies published within the last decade while retaining selected foundational literature that established important methodological concepts.

Data extraction and narrative synthesis

Relevant information was extracted from eligible publications using a structured approach that included study characteristics, psychiatric population, AI methodology, data source, sample size, predictive performance, clinical application, principal findings, strengths, and reported limitations. Rather than performing quantitative meta-analysis, findings were synthesized narratively to identify recurring themes, technological innovations, methodological advancements, and persistent implementation challenges. The evidence was organized into thematic domains including AI-assisted diagnosis, suicide risk prediction, digital phenotyping, neuroimaging, NLP, personalized psychiatry, explainable AI, and ethical governance. This thematic synthesis enabled integration of evidence from heterogeneous study designs while emphasizing clinically meaningful developments.

DIGITAL PHENOTYPING AND SMARTPHONE-BASED MENTAL HEALTH MONITORING

Digital phenotyping has emerged as one of the most innovative applications of AI in psychiatry by enabling continuous, real-world assessment of mental health through smartphones and connected digital devices.³¹⁻³³ Unlike conventional psychiatric evaluations, which are performed intermittently during clinical consultations, digital phenotyping provides longitudinal monitoring of behavioral patterns in patients' natural environments. Smartphones generate large volumes of passive and active data, including mobility patterns, physical activity, screen time, sleep duration, communication frequency, typing dynamics, voice characteristics, geolocation, and social interaction. AI algorithms analyze these multidimensional datasets to identify subtle behavioral changes associated with worsening psychiatric symptoms before they become clinically apparent.

Several studies have demonstrated that reductions in physical activity, disturbed sleep-wake cycles, decreased mobility, social withdrawal, and altered communication behavior frequently precede episodes of depression, mania, anxiety, and psychosis. ML models continuously evaluate these digital biomarkers and generate individualized risk estimates, allowing healthcare

professionals to intervene at earlier stages of disease progression. Such continuous monitoring also supports remote psychiatric care, particularly for individuals residing in underserved or geographically isolated communities where specialist mental health services remain limited. Integration of digital phenotyping into routine psychiatric practice has therefore expanded opportunities for proactive, preventive, and patient-centered mental healthcare while reducing dependence on episodic clinical assessments.³¹⁻³⁴

WEARABLE DEVICES AND REMOTE PATIENT MONITORING

Wearable technologies have significantly enhanced the capability of AI to monitor physiological and behavioral indicators associated with psychiatric disorders. Smartwatches, fitness trackers, biosensors, and other wearable devices continuously record heart rate variability, physical activity, sleep architecture, skin temperature, electrodermal activity, respiratory rate, and other physiological parameters that may reflect psychological stress or emotional dysregulation. AI algorithms integrate these physiological signals with clinical information to identify changes suggestive of relapse, medication non-adherence, anxiety exacerbation, depressive episodes, or manic symptoms.

Evidence indicates that alterations in circadian rhythm, sleep fragmentation, autonomic nervous system activity, and daily movement patterns frequently occur before clinical deterioration in patients with bipolar disorder, schizophrenia, and major depressive disorder. Continuous physiological monitoring enables clinicians to detect early warning signs that might otherwise remain unnoticed until severe symptoms develop. Remote patient monitoring also improves long-term follow-up by reducing unnecessary hospital visits while supporting timely intervention when clinically significant abnormalities are detected. The integration of wearable technology with electronic health records and telepsychiatry platforms has further strengthened continuity of care and facilitated personalized treatment adjustments based on real-time patient data.³⁵⁻³⁷

AI IN SUICIDE RISK PREDICTION

Suicide remains one of the most challenging and devastating outcomes in psychiatric practice. Conventional suicide risk assessment relies predominantly on clinical interviews, patient disclosure, and clinician judgment, which often demonstrate limited predictive accuracy because suicidal ideation fluctuates over time and many individuals may conceal their intentions. AI has emerged as a promising approach for improving suicide risk prediction through the analysis of complex multidimensional datasets that extend beyond traditional clinical assessment.

ML models trained using electronic health records, psychiatric history, emergency department visits, medication patterns, previous self-harm episodes, demographic characteristics, social determinants of health, and digital behavioral data have demonstrated improved predictive performance compared with conventional statistical methods. NLP further enhances suicide prevention by identifying expressions of hopelessness, emotional distress, suicidal ideation, and cognitive changes within clinical documentation, psychotherapy transcripts, and patient-generated text. Several DL models have successfully identified individuals at elevated suicide risk months before clinical events occurred, providing opportunities for targeted preventive interventions, intensive monitoring, and personalized safety planning. Although these predictive systems should never replace comprehensive psychiatric evaluation, they offer valuable decision-support tools that complement clinician expertise and strengthen suicide prevention strategies within modern mental healthcare systems.³⁸⁻⁴⁰

PERSONALIZED MENTAL HEALTHCARE AND PRECISION PSYCHIATRY

AI has accelerated the transition from generalized treatment approaches toward precision psychiatry, in which therapeutic decisions are tailored according to individual biological, psychological, behavioral, and environmental characteristics. Psychiatric treatment outcomes vary considerably between patients because mental disorders arise from complex interactions among genetic susceptibility, neurobiology, psychosocial stressors, lifestyle factors, and environmental influences. Consequently, selecting the most appropriate intervention frequently involves trial-and-error prescribing, prolonged treatment delays, and increased healthcare costs.

ML algorithms integrate multidimensional patient information-including clinical history, neuroimaging findings, genomic profiles, inflammatory biomarkers, cognitive assessments, digital phenotyping data, and previous treatment response-to estimate the probability of therapeutic success for individual patients. These predictive models assist psychiatrists in selecting antidepressants, antipsychotics, mood stabilizers, psychotherapy modalities, neuromodulation techniques, and combined treatment strategies most likely to produce favorable clinical outcomes while minimizing adverse effects. Precision psychiatry therefore supports more efficient treatment selection, improves medication adherence, reduces unnecessary therapeutic switching, and enhances patient satisfaction by facilitating individualized care pathways.

AI also contributes to personalized psychotherapy by identifying patient-specific emotional patterns, behavioral

triggers, coping mechanisms, and symptom trajectories through continuous digital monitoring.

Conversational AI systems and intelligent mental health applications can deliver psychoeducation, symptom tracking, cognitive behavioral therapy exercises, and behavioral activation strategies while maintaining continuous communication between patients and healthcare providers. Although these technologies cannot replace therapeutic relationships established by qualified mental health professionals, they provide valuable adjunctive support that enhances accessibility, continuity, and patient engagement.

EXPLAINABLE AI AND CLINICAL DECISION SUPPORT

As AI becomes increasingly integrated into psychiatric practice, transparency and interpretability have become essential requirements for clinical implementation. Many advanced DL algorithms operate as "black boxes," producing highly accurate predictions without clearly explaining how conclusions are reached. Such limited interpretability reduces clinician confidence, restricts regulatory acceptance, and raises ethical concerns regarding accountability and informed decision-making.

Explainable AI has emerged to address these challenges by providing understandable explanations for algorithmic predictions. Feature importance analysis, attention mechanisms, local interpretable model-agnostic explanations, and Shapley additive explanation techniques enable clinicians to identify the variables contributing most strongly to diagnostic classifications and risk predictions.

Improved transparency enhances clinician trust, facilitates shared decision-making, and supports responsible integration of AI within psychiatric care. Clinical decision-support systems incorporating explainable AI assist psychiatrists by summarizing relevant patient information, highlighting individualized risk factors, recommending evidence-based interventions, and supporting treatment planning without replacing professional clinical judgment.

Overall, the available evidence demonstrates that AI has considerable potential to transform psychiatric practice through earlier diagnosis, more accurate risk prediction, personalized treatment planning, continuous digital monitoring, and improved clinical decision support shown in Table 2. Although important scientific, ethical, and regulatory challenges remain, ongoing advances in ML, multimodal data integration, explainable AI, and precision psychiatry indicate that AI is likely to become an increasingly integral component of future mental healthcare systems.

Table 2: AI techniques used in psychiatry.

AI techniques	Principle	Psychiatric application	Advantages	Limitations
ML	Learns patterns from structured clinical data to make predictions. ¹⁻⁴	Diagnosis of depression, schizophrenia, bipolar disorder, relapse prediction, treatment response prediction.	High predictive accuracy, handles large datasets, supports clinical decision-making.	Requires large, high-quality datasets; susceptible to bias and overfitting.
DL	Multi-layer neural networks automatically extract complex features from high-dimensional data. ²⁻⁵	Neuroimaging analysis, EEG interpretation, psychiatric diagnosis, speech and facial emotion recognition.	Excellent performance with imaging and multimodal datasets; minimal manual feature engineering.	Poor interpretability ("black-box"), computationally intensive.
NLP	Analyzes spoken and written language to identify clinically relevant linguistic patterns. ⁶⁻⁹	Detection of depression, psychosis, suicidal ideation, cognitive impairment, automated clinical documentation.	Rapid analysis of unstructured text; improves early symptom identification.	Language variability, cultural differences, and privacy concerns may affect performance.
Computer vision	Uses image-processing algorithms to interpret facial expressions, eye movements, and behavioral cues. ¹⁰⁻¹²	Emotion recognition, autism assessment, schizophrenia symptom analysis, behavioral monitoring.	Objective behavioral assessment and continuous monitoring.	Sensitive to image quality, lighting conditions, and demographic bias.
Digital phenotyping	Collects passive behavioral data from smartphones and wearable devices. ¹¹⁻¹⁴	Continuous monitoring of mood, sleep, mobility, social interaction, relapse detection, suicide prevention.	Real-time monitoring, early identification of symptom deterioration.	Privacy concerns, missing data, user adherence issues.
Explainable AI (XAI)	Provides transparent explanations for AI predictions to improve interpretability. ¹⁵⁻¹⁷	Clinical decision support, treatment planning, risk prediction, clinician trust.	Enhances transparency, accountability, and acceptance in clinical practice.	May reduce predictive performance and requires additional computational methods.
Reinforcement learning	Learns optimal decision-making through repeated interactions with the environment. ^{18,19}	Personalized treatment optimization, adaptive psychotherapy, medication management.	Supports individualized and dynamic treatment strategies.	Limited psychiatric evidence and complex implementation.
Generative AI (Large language models)	Generates human-like text and synthesizes knowledge using transformer-based neural networks. ²⁰	Mental health chatbots, psychoeducation, documentation support, patient engagement, clinical assistance.	Improves accessibility, communication, and administrative efficiency.	Risk of misinformation, hallucinations, ethical concerns, and need for human oversight.

DISCUSSION

Artificial intelligence is redefining the landscape of psychiatric practice by introducing data-driven approaches that complement conventional clinical assessment and facilitate precision mental healthcare. The findings of this narrative review demonstrate that AI has progressed beyond experimental applications and is increasingly being integrated into diagnostic support, risk prediction, treatment optimization, and continuous patient monitoring. The convergence of ML, DL, NLP, neuroimaging analytics, and digital phenotyping has created unprecedented opportunities to improve the quality, accessibility, and personalization of psychiatric services.¹⁻⁴

One of the most significant observations emerging from the current literature is the ability of AI algorithms to analyze heterogeneous datasets that extend beyond traditional psychiatric interviews. Conventional diagnosis

depends heavily on clinician expertise, patient recall, and behavioral observation, which are inherently subjective and may vary across clinical settings. ML models, in contrast, simultaneously evaluate demographic characteristics, neuroimaging findings, genetic information, electronic health records, physiological biomarkers, speech patterns, and behavioral data to identify complex relationships associated with psychiatric disorders. This multidimensional analytical capability improves diagnostic consistency and may facilitate earlier recognition of conditions such as depression, schizophrenia, bipolar disorder, anxiety disorders, and dementia before symptoms become clinically apparent.⁵⁻⁸

The review also highlights the growing importance of predictive analytics in psychiatry. Early identification of individuals at risk for suicide, psychosis, relapse, treatment resistance, or psychiatric hospitalization remains a major challenge in mental healthcare. AI-based prediction models have consistently demonstrated greater sensitivity

and predictive performance than many conventional statistical approaches because they are capable of identifying nonlinear interactions among numerous clinical variables. These predictive systems enable healthcare professionals to implement preventive interventions, optimize treatment strategies, and intensify monitoring before serious clinical deterioration occurs. Nevertheless, predictive accuracy should not be interpreted as absolute certainty, and algorithmic outputs must always be interpreted within the broader clinical context by experienced mental health professionals.⁹⁻¹²

Digital phenotyping and wearable technologies represent another transformative development identified in this review. Continuous monitoring of sleep, mobility, physical activity, communication patterns, physiological parameters, and smartphone usage provides valuable insight into patients' daily functioning beyond the clinical environment. These digital biomarkers allow earlier detection of behavioral changes that frequently precede depressive episodes, manic relapse, psychosis, or suicidal crises. Integration of real-time behavioral monitoring into psychiatric practice may substantially enhance continuity of care while supporting community-based mental health services and telepsychiatry. However, widespread implementation requires careful attention to patient privacy, informed consent, cybersecurity, and responsible governance because mental health information represents one of the most sensitive categories of personal health data.¹³⁻¹⁶

Personalized psychiatry constitutes another important implication of artificial intelligence. Psychiatric disorders demonstrate considerable heterogeneity in symptom presentation, disease progression, and treatment response, making individualized therapeutic decision-making essential. AI-supported precision psychiatry enables clinicians to estimate treatment response by integrating multidimensional patient information, thereby reducing reliance on trial-and-error prescribing. Predictive algorithms may assist psychiatrists in selecting the most appropriate pharmacological agents, psychotherapeutic interventions, or neuromodulation strategies according to each patient's unique clinical profile. Such individualized treatment planning has the potential to improve clinical outcomes, reduce adverse drug reactions, enhance medication adherence, and optimize healthcare resource utilization.¹⁷⁻²⁰

Despite these promising developments, important limitations continue to restrict the widespread clinical adoption of artificial intelligence in psychiatry. Many ML algorithms are developed using relatively small or geographically restricted datasets, limiting their external validity and generalizability across diverse populations. Differences in ethnicity, socioeconomic conditions, healthcare infrastructure, diagnostic practices, and cultural perceptions of mental illness may influence algorithm performance when applied outside their original development settings. Furthermore, inadequate external

validation, inconsistent reporting standards, and methodological heterogeneity remain significant concerns throughout the current literature. Future investigations should therefore prioritize multicenter prospective studies involving diverse populations to improve algorithm robustness and reproducibility.²¹⁻²⁸

Ethical considerations remain central to the responsible implementation of artificial intelligence within psychiatric practice. Algorithmic bias may unintentionally reinforce existing healthcare disparities if training datasets inadequately represent vulnerable populations.

Similarly, limited interpretability of complex DL models raises concerns regarding transparency, accountability, and clinician trust. Explainable artificial intelligence has emerged as a promising solution by providing understandable explanations for algorithmic recommendations, thereby supporting shared decision-making and enhancing clinician confidence. Regulatory frameworks addressing data governance, algorithm validation, accountability, and patient safety must continue evolving alongside technological innovation to ensure that AI applications remain ethical, equitable, and clinically reliable.²⁵⁻²⁸

Importantly, the evidence synthesized in this review strongly suggests that artificial intelligence should be viewed as an adjunct rather than a replacement for psychiatrists and other mental health professionals. Psychiatric care extends far beyond diagnostic classification and includes empathy, therapeutic alliance, cultural sensitivity, ethical reasoning, communication, and individualized clinical judgment. These uniquely human attributes cannot currently be replicated by computational systems. Instead, AI should function as an intelligent clinical decision-support tool that enhances professional expertise, reduces administrative burden, improves diagnostic confidence, and facilitates evidence-informed treatment planning while preserving patient-centered care.²⁹⁻³²

Future research should emphasize multimodal artificial intelligence capable of integrating neuroimaging, genomics, digital phenotyping, wearable sensor data, electronic health records, and patient-reported outcomes within unified predictive frameworks. Advances in federated learning, privacy-preserving ML, explainable AI, and large language models are expected to further enhance diagnostic precision while protecting patient confidentiality.

In addition, international collaboration among psychiatrists, psychologists, neuroscientists, data scientists, ethicists, engineers, policymakers, and patient representatives will be essential for establishing standardized reporting guidelines, validation protocols, and regulatory frameworks that promote safe clinical implementation.³³⁻⁴⁰

CONCLUSION

Artificial intelligence is transforming psychiatric care by enhancing diagnostic accuracy, improving risk prediction, enabling personalized treatment, and supporting continuous patient monitoring. Advances in ML, DL, NLP, digital phenotyping, neuroimaging, and wearable technologies have strengthened clinicians' ability to identify complex patterns associated with mental disorders, facilitating earlier intervention and more precise clinical decision-making. AI-driven predictive models and clinical decision-support systems have demonstrated considerable potential for identifying individuals at risk of relapse, suicide, and treatment resistance while promoting precision psychiatry through individualized therapeutic strategies. Despite these promising developments, challenges related to algorithmic bias, data privacy, model transparency, regulatory oversight, and equitable access remain significant barriers to widespread clinical implementation. Addressing these issues through rigorous validation, explainable AI, standardized reporting, and robust ethical governance is essential to ensure safe and responsible integration into routine psychiatric practice.

Importantly, artificial intelligence should complement rather than replace psychiatrists, preserving the therapeutic relationship, clinical expertise, and patient-centered approach that remain fundamental to mental healthcare. Continued multidisciplinary collaboration and high-quality research will be critical to advancing trustworthy AI systems that improve the accessibility, effectiveness, and quality of psychiatric care while supporting the future of precision mental health.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: opportunities and challenges. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2018;3(3):223-30.
2. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44-56.
3. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. *Nat Med*. 2019;25(1):24-9.
4. Dwyer DB, Falkai P, Koutsouleris N. Machine learning approaches for clinical psychology and psychiatry. *Annu Rev Clin Psychol*. 2018;14:91-118.
5. Shatte ABR, Hutchinson DM, Teague SJ. Machine learning in mental health: a scoping review of methods and applications. *Psychol Med*. 2019;49(9):1426-48.
6. Chekroud AM, Bondar J, Delgadillo J, Doherty G, Wasil A, Fokkema M, et al. The promise of machine learning in predicting treatment outcomes in psychiatry. *World Psychiatry*. 2021;20(2):154-70.
7. Torous J, Wisniewski H, Liu G, Keshavan M. Mental health mobile phone app usage, concerns, and benefits among psychiatric patients. *JMIR Ment Health*. 2018;5(4):e11715.
8. Vaidyam AN, Wisniewski H, Halamka JD, Kashavan MS, Torous J. Chatbots and conversational agents in mental health: a review of the psychiatric landscape. *Can J Psychiatry*. 2019;64(7):456-64.
9. Fitzpatrick KK, Darcy A, Vierhile M. Delivering cognitive behavioral therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (Woebot): a randomized controlled trial. *JMIR Ment Health*. 2017;4(2):e19.
10. Fiske A, Henningsen P, Buyx A. Your robot therapist will see you now: ethical implications of embodied artificial intelligence in psychiatry, psychology, and psychotherapy. *J Med Internet Res*. 2019;21(5):e13216.
11. Insel TR. Digital phenotyping: technology for a new science of behavior. *JAMA*. 2017;318(13):1215-6.
12. Torous J, Onnela JP, Keshavan M. New dimensions and new tools to realize the potential of RDoC: digital phenotyping via smartphones and connected devices. *Transl Psychiatry*. 2017;7(3):e1053.
13. Huckvale K, Venkatesh S, Christensen H. Toward clinical digital phenotyping: a timely opportunity to consider purpose, quality, and safety. *NPJ Digit Med*. 2019;2:88.
14. Gooding P. Mapping the rise of digital mental health technologies: emerging issues for law and society. *Int J Law Psychiatry*. 2019;67:101498.
15. Graham S, Depp C, Lee EE, Nebeker C, Tu X, Kim HC, et al. Artificial intelligence for mental health and mental illnesses: an overview. *Curr Psychiatry Rep*. 2019;21(11):116.
16. Koutsouleris N, Dwyer DB, Degenhardt F, Maj C, Urquijo-Castro MF, Sanfelici R, et al. Multimodal machine learning workflows for prediction of psychosis. *Mol Psychiatry*. 2022;27:997-1006.
17. Walsh CG, Ribeiro JD, Franklin JC. Predicting suicide attempts in adolescents with machine learning. *Clin Psychol Sci*. 2018;6(3):457-69.
18. Bernert RA, Hilberg AM, Melia R, Kim JP, Shah NH, Abnoui F. Artificial intelligence and suicide prevention: a systematic review of machine learning investigations. *Int J Environ Res Public Health*. 2020;17(16):5929.
19. Sendak MP, D'Arcy J, Kashyap S, Gao M, Nichols M, Corey K, et al. A path for translation of machine learning products into healthcare delivery. *EMJ Innov*. 2020;4(1):1-8.
20. Sun J, Cao R, Zhou M, et al. Artificial intelligence in psychiatry research, diagnosis, and therapy. *Asian J Psychiatr*. 2023;88:103746.
21. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. *Nat Med*. 2022;28(1):31-8.

22. Koutsouleris N, Meisenzahl EM, Davatzikos C, Bottlender R, Frodl T, Scheuerecker J, et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. *Arch Gen Psychiatry.* 2009;66(7):700-12.
23. Abi-Dargham A, Horga G. The search for imaging biomarkers in psychiatric disorders. *Nat Med.* 2016;22(11):1248-55.
24. Durstewitz D, Koppe G, Meyer-Lindenberg A. Deep neural networks in psychiatry. *Mol Psychiatry.* 2019;24(11):1583-98.
25. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature.* 2015;521(7553):436-44.
26. Beam AL, Kohane IS. Big data and machine learning in health care. *JAMA.* 2018;319(13):1317-8.
27. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. *BMC Med.* 2019;17:195.
28. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. *Science.* 2019;366(6464):447-53.
29. Topol EJ. Welcoming new guidelines for AI clinical research. *Nat Med.* 2020;26(9):1318-20.
30. World Health Organization. Ethics and governance of artificial intelligence for health: WHO guidance. Geneva: World Health Organization; 2021. Available at: <https://www.who.int/publications/i/item/9789240029200>. Accessed on 02 August 2026.
31. World Health Organization. Mental health atlas 2020. Geneva: World Health Organization. 2021. Available at: <https://www.who.int/publications/i/item/9789240036703>. Accessed on 02 August 2026.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text Revision (DSM-5-TR). Washington (DC): American Psychiatric Association Publishing. 2022. Available at: <https://www.psychiatry.org/psychiatrists/practice/dsm>. Accessed on 02 August 2026.
33. Cortes C, Vapnik V. Support-vector networks. *Mach Learn.* 1995;20(3):273-97.
34. Breiman L. Random forests. *Mach Learn.* 2001;45(1):5-32.
35. Vaswani A, Shazeer N, Parmar N, Uszkoreit J, Jones L, Gomez AN, et al. Attention is all you need. *Adv Neural Inf Process Syst.* 2017;30:5998-6008.
36. Devlin J, Chang MW, Lee K, Toutanova K. BERT: Pre-training of deep bidirectional transformers for language understanding. In: Proceedings of NAACL-HLT 2019. Minneapolis (MN): Association for Computational Linguistics. 2019;4171-86.
37. Ribeiro MT, Singh S, Guestrin C. "Why should I trust you?": Explaining the predictions of any classifier. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. 2016;1135-44.
38. Lundberg SM, Lee SI. A unified approach to interpreting model predictions. In: Advances in Neural Information Processing Systems. 2017;30:4765-74.
39. Jordan MI, Mitchell TM. Machine learning: Trends, perspectives, and prospects. *Science.* 2015;349(6245):255-60.
40. Esteva A, Chou K, Yeung S, Naik N, Madani A, Mottaghi A, et al. Deep learning-enabled medical computer vision. *NPJ Digit Med.* 2021;4:5.

Cite this article as: Banoo R, Sharma S, Nathiya K, Solomon SG, Mazumdar PS, Aruna T, et al. Artificial intelligence in psychiatry: transforming diagnosis, risk prediction and personalized mental healthcare – a narrative review. *Int J Res Med Sci* 2026;14:4863-71.